文献速递肿瘤 PET/CT甲状腺核医学

整合PET/CT影像组学与糖代谢相关基因特征的放射基因组学预后模型用于非小细胞肺癌的构建与验证

Development and validation of a radiogenomics prognostic model integrating PET/CT radiomics and glucose metabolism-related gene signatures for non-small cell lung cancer.
PubMed 文献 · Eur J Nucl Med Mol Imaging · 2025-05-27

研究从TCIA数据库156例非小细胞肺癌患者的PET/CT图像提取影像组学特征,并结合TCGA和GEO数据库的糖代谢相关基因特征,采用LASSO回归构建多模态放射基因组学预后模型RGC-score。该模型可将患者分为高风险与低风险组,两组生存结局差异有统计学意义(P < 0.001),1年AUC为0.907、5年AUC为0.968。糖代谢相关基因主要参与肿瘤代谢重塑过程,与免疫微环境(尤其是CD8+ T细胞浸润)及免疫检查点分子表达密切相关,不同糖代谢亚型间药物敏感性存在显著差异。

要点

  • RGC-score模型将非小细胞肺癌分为高风险与低风险组,两组生存差异有统计学意义(P < 0.001)。
  • 模型预测性能:1年AUC为0.907,5年AUC为0.968。
  • 糖代谢相关基因参与肿瘤代谢重塑,与CD8+ T细胞浸润和免疫检查点分子表达相关。

核心结论

  • RGC-score能稳健预测非小细胞肺癌预后,并为个体化治疗提供代谢-免疫相互作用的信息。
  • 局限性包括回顾性设计和验证队列规模有限,需要前瞻性多中心试验。

研究设计与样本

  • 从TCIA数据库156例非小细胞肺癌患者的PET/CT图像提取影像组学特征。
  • 糖代谢相关基因特征来自TCGA和GEO数据库。
  • 采用LASSO回归构建结合PET/CT影像组学与糖代谢相关基因的多模态放射基因组学预后模型RGC-score。
  • 进行功能富集分析、免疫浸润评估和药物敏感性分析以探究糖代谢相关基因的生物学意义。

主要发现

  • RGC-score模型将非小细胞肺癌患者分为高风险与低风险组,两组生存结局差异有统计学意义(P < 0.001)。
  • 模型预测性能:1年AUC为0.907,5年AUC为0.968。
  • 糖代谢相关基因主要参与肿瘤代谢重塑过程,与免疫微环境(尤其是CD8+ T细胞浸润)及免疫检查点分子表达密切相关。
  • 不同糖代谢亚型间药物敏感性存在显著差异。

关键数值与推荐

  • RGC-score模型区分高风险与低风险组生存差异的P < 0.001。
  • RGC-score模型1年AUC为0.907,5年AUC为0.968。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 回顾性设计。
  • 验证队列规模有限。
  • 需要前瞻性多中心试验。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Non-small cell lung cancer (NSCLC) is a highly heterogeneous malignancy characterized by altered glucose metabolism. Integration of PET/CT radiomics with glucose metabolism-related genomic signatures could provide a more comprehensive approach for prognosis and treatment guidance. METHODS: Radiomics features were extracted from PET/CT images of 156 NSCLC patients from The Cancer Imaging Archive (TCIA) database, and glucose metabolism-related gene signatures were obtained from TCGA and GEO databases. We developed a multimodal radiogenomics prognostic model (RGC-score) using least absolute shrinkage and selection operator (LASSO) regression, combining PET/CT radiomics, glucose metabolism-related genes (GMR-genes). Functional enrichment analysis, immune infiltration assessment, and drug sensitivity analysis were performed to investigate the biological significance of glucose metabolism-related genes (GMR-genes). RESULTS: The RGC-score model effectively stratified NSCLC patients into distinct high- and low-risk groups with significant differences in survival outcomes (P < 0.001), demonstrating excellent predictive performance (1-year AUC = 0.907, 5-year AUC = 0.968).GMR-genes are mainly involved in the process of metabolic remodeling of tumors, which is closely related to the immune microenvironment (especially CD8+ T cell infiltration) and immune checkpoint molecule expression. Additionally, significant differences in drug sensitivity were identified between glucose metabolism subtypes. CONCLUSION: The RGC-score robustly predicts NSCLC prognosis and informs metabolic-immune interactions for personalized therapy. Limitations include the retrospective design and modest validation cohort size, necessitating prospective multicenter trials.

来源:Eur J Nucl Med Mol Imaging,查看原文。版权归原作者所有。

引用

  1. Wang C, Wang C, Zhang J, et al. Development and validation of a radiogenomics prognostic model integrating PET/CT radiomics and glucose metabolism-related gene signatures for non-small cell lung cancer. Eur J Nucl Med Mol Imaging. 2025. PMID: 40423774. doi:10.1007/s00259-025-07354-4

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。